KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy
Favazza, Laura A., Parseghian, Christine M., Kaya, Cihan, Nikiforova, Marina N., Roy, Somak, Wald, Abigail I., Landau, Michael S., Proksell, Siobhan S., Dueker, Jeffrey M., Johnston, Elyse R., Brand,Journal:
Modern Pathology
DOI:
10.1038/s41379-020-0560-x
Date:
May, 2020
File:
PDF, 2.10 MB
2020
File converter
More search results
More benefits 
